ArticleEuropean radiology2026
Deep learning reconstruction of zero echo time magnetic resonance imaging: diagnostic performance in axial spondyloarthritis.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions.European radiology experimental · 2026Trial
- Deep learning-based chemical shift-artifact correction of ZTE MRI for enhanced bone depiction of the lumbar spine.Skeletal radiology · 2026Article
- What is the Impact of Applying Deep Learning Reconstruction to Zero Echo Time MRI on the Evaluation of Osseous Lesions in Axial Spondyloarthritis?Journal of the Korean Society of Radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the diagnostic performance of deep learning reconstruction (DLR) of zero echo time (ZTE) MRI for structural lesions in patients with axial spondyloarthritis, against T1WI and ZTE MRI without DLR, using CT as the reference standard. MATERIALS AND
methodsFrom February 2021 to December 2022, 26 patients (52 sacroiliac joints (SIJ) and 104 quadrants) underwent SIJ MRIs. Three readers assessed overall image quality and structural conspicuity, scoring SIJs for structural lesions on T1WI, ZTE, and ZTE DLR 50%, 75%, and 100%, respectively. Diagnostic performance was evaluated using CT as the reference standard, and inter-reader agreement was assessed using weighted kappa.
resultsZTE DLR 100% showed the highest image quality scores for readers 1 and 2, and the best structural conspicuity scores for all three readers. In readers 2 and 3, ZTE DLR 75% showed the best diagnostic performance for bone sclerosis, outperforming T1WI and ZTE (all p < 0.05). In all readers, ZTE DLR 100% showed superior diagnostic performance for bone erosion compared to T1WI and ZTE (all p < 0.01). For bone sclerosis, ZTE DLR 50% showed the highest kappa coefficients between readers 1 and 2 and between readers 1 and 3. For bone erosion, ZTE DLR 100% showed the highest kappa coefficients between readers.
conclusionZTE MRI with DLR outperformed T1WI and ZTE MRI without DLR in diagnosing bone sclerosis and erosion of the SIJ, while offering similar subjective image quality and structural conspicuity. KEY POINTS: Question With zero echo time (ZTE) alone, small structural lesions, such as bone sclerosis and erosion, are challenging to confirm in axial spondyloarthritis. Findings ZTE deep learning reconstruction (DLR) showed higher diagnostic performance for detecting bone sclerosis and erosion, compared with T1WI and ZTE. Clinical relevance Applying DLR to ZTE enhances diagnostic capability for detecting bone sclerosis and erosion in the sacroiliac joint, aiding in the early diagnosis of axial spondyloarthritis.
Indexed as
Identifiers
40707731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.